Wall Street brokerages forecast that Prevail Therapeutics Inc. (NASDAQ:PRVL) will post earnings per share of ($0.50) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Prevail Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.55). The company is expected to announce its next quarterly earnings report on Wednesday, November 13th.

According to Zacks, analysts expect that Prevail Therapeutics will report full-year earnings of ($2.53) per share for the current year, with EPS estimates ranging from ($3.30) to ($2.07). For the next year, analysts expect that the business will post earnings of ($2.11) per share, with EPS estimates ranging from ($2.48) to ($1.91). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Prevail Therapeutics.

Prevail Therapeutics (NASDAQ:PRVL) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.58) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.24) by $0.66.

Several equities analysts recently commented on the company. Morgan Stanley assumed coverage on Prevail Therapeutics in a research report on Monday, July 15th. They set an “overweight” rating and a $20.00 target price for the company. Cowen assumed coverage on Prevail Therapeutics in a research report on Monday, July 15th. They set an “outperform” rating for the company. Bank of America assumed coverage on Prevail Therapeutics in a research report on Monday, July 15th. They set a “buy” rating and a $15.00 target price for the company. Zacks Investment Research upgraded Prevail Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Thursday, October 17th. Finally, Wedbush restated a “buy” rating and set a $20.00 target price on shares of Prevail Therapeutics in a research report on Friday, November 1st. Five research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average price target of $16.50.

Institutional investors and hedge funds have recently modified their holdings of the business. Blackstone Group Inc bought a new position in Prevail Therapeutics in the 2nd quarter valued at $66,000. Point72 Hong Kong Ltd bought a new position in Prevail Therapeutics in the 2nd quarter valued at $106,000. Morgan Stanley bought a new position in Prevail Therapeutics in the 2nd quarter valued at $166,000. Northern Trust Corp bought a new position in Prevail Therapeutics in the 2nd quarter valued at $188,000. Finally, SG Americas Securities LLC bought a new position in Prevail Therapeutics in the 2nd quarter valued at $194,000. Hedge funds and other institutional investors own 77.49% of the company’s stock.

Shares of NASDAQ PRVL traded up $1.12 during mid-day trading on Friday, reaching $12.30. 95,300 shares of the company traded hands, compared to its average volume of 107,080. The company has a debt-to-equity ratio of 0.04, a quick ratio of 26.94 and a current ratio of 26.94. Prevail Therapeutics has a fifty-two week low of $7.41 and a fifty-two week high of $16.90. The company’s fifty day moving average is $11.27.

Prevail Therapeutics Company Profile

Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.

Read More: Elliott Wave Theory

Get a free copy of the Zacks research report on Prevail Therapeutics (PRVL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prevail Therapeutics (NASDAQ:PRVL)

Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.